Kong Garheng 4

What Happened

• Director Kong Garheng received equity awards from Xeris Biopharma on June 4, 2026: 24,193 restricted stock units (RSUs) granted (acquired at $0) and 32,996 derivative securities reported as stock options with an exercise price of $6.15 (total shown as $202,925). These are grants/awards, not open-market purchases or sales.

Key Details

• Transaction date: June 4, 2026; Form 4 filed June 5, 2026 (no late filing indicated).
• Grants: 24,193 RSUs (value reported as $0 on grant); 32,996 options at $6.15 exercise ($202,925 shown).
• Vesting: Both awards vest in full upon the earlier of June 4, 2026 or the Company’s next annual meeting of stockholders, subject to continued service (see footnotes F1 and F2).
• Shares owned after transaction: Not specified in the filing.
• Transaction codes: A = Award/Grant; derivative code notes these are stock options (not exercised or sold).

Context

• RSUs represent a contingent right to receive one share per unit upon vesting; they are not immediate cash purchases or sales.
• The derivative entry reflects option grants (strike $6.15). This report does not show exercises, sales, or cashless transactions — only the grant of awards.
• Grants to directors are common and often part of compensation; they are informational rather than definitive signals of personal trading intent.